Abstract YO23
Case summary
Soft tissue Giant cell tumor presented as Nasopharyngeal mass : A case Report
ABSTRACT:
Background:
Primary soft tissue giant cell tumors are exceedingly rare. These often present in the elderly and are mostly noted on the extremities. Morphologically, these tumors resemble their osseous counterparts but sequencing studies have suggested that these two may be genetically distinct. Surgical extirpation remains standard of treatment; but for those with unresectable disease treatment options are less clear. For these patients, the use of bisphosphonates and RANK-L directed biologic therapy have been reported in the literature.
Case presentation:
A 30 year old male consulted at our medical oncology clinic with the chief complaint of diplopia. Magnetic resonance imaging (MRI) of the head revealed an enhancing soft tissue mass at the nasopharyngeal wall measuring 5.8x5.5x5.1cm extending anteriorly at the posterior margin of the nasal cavity, both parasellar regions, leptomeningeal region of the medial aspect of both middle cranial fossa, and infiltrating into the clivus. No distant metastasis was seen. Punch biopsy of this nasopharyngeal mass favored a giant cell tumor. Immunohistochemical staining was done with the following results: Cytokeratin negative, CD68 positive, and Vimentin positive, all consistent with giant cell tumor. Due to its location, the tumor was regarded to be unresectable. Zoledronic acid was given once every 28 days for 3 months. Cranial CT scan done after three months of treatment revealed an enhancing nasopharyngeal mass measuring 6.0x5.0x4.0cm with intracranial extension. At this time despite demonstrating stable disease, the patient was noted to have worsening of symptoms and was then shifted to Denosumab.
Conclusion:
We have reported a case of a nasopharyngeal giant cell tumor, which is an uncommon presentation of a rare soft tissue tumor. While surgery is the preferred treatment for this disease, the location of this tumor precluded resection. This has prompted the decision to employ systemic treatment with Zoledronic acid and subsequently Denosumab for this patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract